James B. Tananbaum - Net Worth and Insider Trading

James B. Tananbaum Net Worth

The estimated net worth of James B. Tananbaum is at least $217 Million dollars as of 2024-11-06. James B. Tananbaum is the Director, 10% Owner of Alumis Inc and owns about 15,152,954 shares of Alumis Inc (ALMS) stock worth over $181 Million. James B. Tananbaum is also the Director, 10% Owner of Kinnate Biopharma Inc and owns about 13,718,311 shares of Kinnate Biopharma Inc (KNTE) stock worth over $36 Million. Details can be seen in James B. Tananbaum's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that James B. Tananbaum has not made any transactions after 2024-07-01 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of James B. Tananbaum

James B. Tananbaum Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, James B. Tananbaum owns 11 companies in total, including FS Development Corp (FSDC) , 10x Genomics Inc (TXG) , and Aerie Pharmaceuticals Inc (AERI) among others .

Click here to see the complete history of James B. Tananbaum’s form 4 insider trades.

Insider Ownership Summary of James B. Tananbaum

Ticker	Comapny	Transaction Date	Type of Owner
FSDC	FS Development Corp	2020-08-14	director & 10 percent owner & President & CEO
TXG	10x Genomics Inc	2020-03-04	10 percent owner
AERI	Aerie Pharmaceuticals Inc	2016-07-22	10 percent owner
		2016-08-18	10 percent owner
		2016-05-05	10 percent owner
		2021-02-05	10 percent owner
		2023-05-08	director & 10 percent owner
		2021-06-10	director
		2021-10-04	director & 10 percent owner
		2021-12-23	director & 10 percent owner
		2022-06-09	10 percent owner

James B. Tananbaum Latest Holdings Summary

James B. Tananbaum currently owns a total of 2 stocks. Among these stocks, James B. Tananbaum owns 15,152,954 shares of Alumis Inc (ALMS) as of July 1, 2024, with a value of $181 Million and a weighting of 83.28%. James B. Tananbaum also owns 13,718,311 shares of Kinnate Biopharma Inc (KNTE) as of May 8, 2023, with a value of $36 Million and a weighting of 16.72%.

Latest Holdings of James B. Tananbaum

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
ALMS	Alumis Inc	2024-07-01	15,152,954	11.95	181,077,800
KNTE	Kinnate Biopharma Inc	2023-05-08	13,718,311	2.65	36,353,524

Holding Weightings of James B. Tananbaum

James B. Tananbaum Form 4 Trading Tracker

According to the SEC Form 4 filings, James B. Tananbaum has made a total of 1 transactions in Alumis Inc (ALMS) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Alumis Inc is the acquisition of 2,500,000 shares on July 1, 2024, which cost James B. Tananbaum around $40 Million.

According to the SEC Form 4 filings, James B. Tananbaum has made a total of 2 transactions in Kinnate Biopharma Inc (KNTE) over the past 5 years, including 2 buys and 0 sells. The most-recent trade in Kinnate Biopharma Inc is the acquisition of 1,780,000 shares on May 8, 2023, which cost James B. Tananbaum around $5 Million.

Insider Trading History of James B. Tananbaum

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

James B. Tananbaum Trading Performance

GuruFocus tracks the stock performance after each of James B. Tananbaum's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by James B. Tananbaum is -13.97%. GuruFocus also compares James B. Tananbaum's trading performance to market benchmark return within the same time period. The performance of stocks bought by James B. Tananbaum within 3 months outperforms 0 times out of 3 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how James B. Tananbaum's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of James B. Tananbaum

Average Return

Average return per transaction

Outperforming Transactions

0 out of 1 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	7.81
Relative Return to S&P 500(%)	5.92

James B. Tananbaum Ownership Network

Ownership Network List of James B. Tananbaum

No Data

Ownership Network Relation of James B. Tananbaum

James B. Tananbaum Owned Company Details

What does FS Development Corp do?

Who are the key executives at FS Development Corp?

James B. Tananbaum is the director & 10 percent owner & President & CEO of FS Development Corp. Other key executives at FS Development Corp include 10 percent owner Foresite Capital Fund V, L.p. , 10 percent owner Foresite Capital Management V, Llc , and 10 percent owner Fs Development Holdings, Llc .

FS Development Corp (FSDC) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of FS Development Corp (FSDC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of FS Development Corp (FSDC) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

FS Development Corp (FSDC)'s detailed insider trading history can be found in Insider Trading Tracker table.

FS Development Corp Insider Transactions

No Available Data

What does 10x Genomics Inc do?

Who are the key executives at 10x Genomics Inc?

James B. Tananbaum is the 10 percent owner of 10x Genomics Inc. Other key executives at 10x Genomics Inc include director & 10 percent owner & Chief Executive Officer Serge Saxonov , director & See Remarks Benjamin J. Hindson , and Chief Financial Officer Justin J. Mcanear .

10x Genomics Inc (TXG) Insider Trades Summary

Over the past 18 months, James B. Tananbaum made no insider transaction in 10x Genomics Inc (TXG). Other recent insider transactions involving 10x Genomics Inc (TXG) include a net sale of 93,946 shares made by Serge Saxonov , a net sale of 41,247 shares made by Benjamin J. Hindson , and a net sale of 12,784 shares made by Justin J. Mcanear .

In summary, during the past 3 months, insiders sold 14,061 shares of 10x Genomics Inc (TXG) in total and bought 0 shares, with a net sale of 14,061 shares. During the past 18 months, 219,174 shares of 10x Genomics Inc (TXG) were sold and 0 shares were bought by its insiders, resulting in a net sale of 219,174 shares.

10x Genomics Inc (TXG)'s detailed insider trading history can be found in Insider Trading Tracker table.

10x Genomics Inc Insider Transactions

No Available Data

What does Aerie Pharmaceuticals Inc do?

Who are the key executives at Aerie Pharmaceuticals Inc?

James B. Tananbaum is the 10 percent owner of Aerie Pharmaceuticals Inc. Other key executives at Aerie Pharmaceuticals Inc include Chief Financial Officer Peter Frederick Lang , director & Chief Executive Officer Raj Kannan , and Vice President of Finance Jeffrey Calabrese .

Aerie Pharmaceuticals Inc (AERI) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Aerie Pharmaceuticals Inc (AERI) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aerie Pharmaceuticals Inc (AERI) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Aerie Pharmaceuticals Inc (AERI)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aerie Pharmaceuticals Inc Insider Transactions

No Available Data

What does Aimmune Therapeutics Inc do?

Who are the key executives at Aimmune Therapeutics Inc?

James B. Tananbaum is the 10 percent owner of Aimmune Therapeutics Inc. Other key executives at Aimmune Therapeutics Inc include 10 percent owner Societe Des Produits Nestle S.a. , Chief Financial Officer Eric Bjerkholt , and Chief Medical Officer Adelman Daniel C Md .

Aimmune Therapeutics Inc (AIMT) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Aimmune Therapeutics Inc (AIMT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aimmune Therapeutics Inc (AIMT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Aimmune Therapeutics Inc (AIMT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aimmune Therapeutics Inc Insider Transactions

No Available Data

What does Intellia Therapeutics Inc do?

Who are the key executives at Intellia Therapeutics Inc?

James B. Tananbaum is the 10 percent owner of Intellia Therapeutics Inc. Other key executives at Intellia Therapeutics Inc include EVP & Chief Technical Officer Eliana Clark , EVP & Chief Scientific Officer Laura Sepp-lorenzino , and EVP & Chief Business Officer Derek Hicks .

Intellia Therapeutics Inc (NTLA) Insider Trades Summary

Over the past 18 months, James B. Tananbaum made no insider transaction in Intellia Therapeutics Inc (NTLA). Other recent insider transactions involving Intellia Therapeutics Inc (NTLA) include a net sale of 10,373 shares made by Eliana Clark , a net sale of 2,397 shares made by Muna Bhanji , and a net sale of 7,807 shares made by Laura Sepp-lorenzino .

In summary, during the past 3 months, insiders sold 2,012 shares of Intellia Therapeutics Inc (NTLA) in total and bought 0 shares, with a net sale of 2,012 shares. During the past 18 months, 62,207 shares of Intellia Therapeutics Inc (NTLA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 62,207 shares.

Intellia Therapeutics Inc (NTLA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Intellia Therapeutics Inc Insider Transactions

No Available Data

What does Aclaris Therapeutics Inc do?

Who are the key executives at Aclaris Therapeutics Inc?

James B. Tananbaum is the 10 percent owner of Aclaris Therapeutics Inc. Other key executives at Aclaris Therapeutics Inc include Chief Scientific Officer Joseph Monahan , Chief Financial Officer Kevin Balthaser , and Chief Business Officer James Loerop .

Aclaris Therapeutics Inc (ACRS) Insider Trades Summary

Over the past 18 months, James B. Tananbaum made no insider transaction in Aclaris Therapeutics Inc (ACRS). Other recent insider transactions involving Aclaris Therapeutics Inc (ACRS) include a net purchase of 4,854,052 shares made by Braden Michael Leonard , a net sale of 18,000 shares made by Joseph Monahan , and a net purchase of 14,705 shares made by James Loerop .

In summary, during the past 3 months, insiders sold 0 shares of Aclaris Therapeutics Inc (ACRS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 18,000 shares of Aclaris Therapeutics Inc (ACRS) were sold and 4,878,247 shares were bought by its insiders, resulting in a net purchase of 4,860,247 shares.

Aclaris Therapeutics Inc (ACRS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aclaris Therapeutics Inc Insider Transactions

No Available Data

What does Kinnate Biopharma Inc do?

Who are the key executives at Kinnate Biopharma Inc?

James B. Tananbaum is the director & 10 percent owner of Kinnate Biopharma Inc. Other key executives at Kinnate Biopharma Inc include 10 percent owner Foresite Capital Fund Iv, L.p. , director & 10 percent owner Orbimed Capital Gp Viii Llc , and director & 10 percent owner Orbimed Advisors Iv Ltd .

Kinnate Biopharma Inc (KNTE) Insider Trades Summary

Over the past 18 months, James B. Tananbaum made 1 insider transaction in Kinnate Biopharma Inc (KNTE) with a net purchase of 1,780,000. Other recent insider transactions involving Kinnate Biopharma Inc (KNTE) include a net purchase of 1,780,000 shares made by Foresite Capital Fund Iv, L.p. ,

In summary, during the past 3 months, insiders sold 0 shares of Kinnate Biopharma Inc (KNTE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Kinnate Biopharma Inc (KNTE) were sold and 3,560,000 shares were bought by its insiders, resulting in a net purchase of 3,560,000 shares.

Kinnate Biopharma Inc (KNTE)'s detailed insider trading history can be found in Insider Trading Tracker table.

Kinnate Biopharma Inc Insider Transactions

No Available Data

What does Quantum-Si Inc do?

Who are the key executives at Quantum-Si Inc?

James B. Tananbaum is the director of Quantum-Si Inc. Other key executives at Quantum-Si Inc include Chief Financial Officer Jeffry R. Keyes , director & Chief Executive Officer Jeffrey Alan Hawkins , and General Counsel & Corp. Secr. Christian Lapointe .

Quantum-Si Inc (QSI) Insider Trades Summary

Over the past 18 months, James B. Tananbaum made no insider transaction in Quantum-Si Inc (QSI). Other recent insider transactions involving Quantum-Si Inc (QSI) include a net purchase of 100,000 shares made by Jeffry R. Keyes , a net purchase of 50,000 shares made by Jeffrey Alan Hawkins , and a net purchase of 35,000 shares made by Christian Lapointe .

In summary, during the past 3 months, insiders sold 4,309 shares of Quantum-Si Inc (QSI) in total and bought 270,000 shares, with a net purchase of 265,691 shares. During the past 18 months, 11,837 shares of Quantum-Si Inc (QSI) were sold and 355,000 shares were bought by its insiders, resulting in a net purchase of 343,163 shares.

Quantum-Si Inc (QSI)'s detailed insider trading history can be found in Insider Trading Tracker table.

Quantum-Si Inc Insider Transactions

No Available Data

What does Disc Medicine Inc do?

Who are the key executives at Disc Medicine Inc?

James B. Tananbaum is the director & 10 percent owner of Disc Medicine Inc. Other key executives at Disc Medicine Inc include Chief Medical Officer William Jacob Savage , director & 10 percent owner Orbimed Advisors Llc , and director & 10 percent owner Mona Ashiya .

Disc Medicine Inc (IRON) Insider Trades Summary

Over the past 18 months, James B. Tananbaum made no insider transaction in Disc Medicine Inc (IRON). Other recent insider transactions involving Disc Medicine Inc (IRON) include a net sale of 40,789 shares made by William Richard White , a net sale of 75,429 shares made by Kevin Bitterman , and a net sale of 1,106,612 shares made by Atlas Venture Fund X, L.p. .

In summary, during the past 3 months, insiders sold 5,158 shares of Disc Medicine Inc (IRON) in total and bought 0 shares, with a net sale of 5,158 shares. During the past 18 months, 3,907,384 shares of Disc Medicine Inc (IRON) were sold and 388,891 shares were bought by its insiders, resulting in a net sale of 3,518,493 shares.

Disc Medicine Inc (IRON)'s detailed insider trading history can be found in Insider Trading Tracker table.

Disc Medicine Inc Insider Transactions

No Available Data

What does Pardes Biosciences Inc do?

Who are the key executives at Pardes Biosciences Inc?

James B. Tananbaum is the director & 10 percent owner of Pardes Biosciences Inc. Other key executives at Pardes Biosciences Inc include 10 percent owner Fs Development Holdings Ii, Llc , 10 percent owner Foresite Capital Fund V, L.p. , and 10 percent owner Foresite Capital Opportunity Fund V, L.p. .

Pardes Biosciences Inc (PRDS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Pardes Biosciences Inc (PRDS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Pardes Biosciences Inc (PRDS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Pardes Biosciences Inc (PRDS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Pardes Biosciences Inc Insider Transactions

No Available Data

What does Theseus Pharmaceuticals Inc do?

Who are the key executives at Theseus Pharmaceuticals Inc?

James B. Tananbaum is the 10 percent owner of Theseus Pharmaceuticals Inc. Other key executives at Theseus Pharmaceuticals Inc include director & 10 percent owner Carl L Gordon , director & 10 percent owner Orbimed Advisors Llc , and 10 percent owner Foresite Capital Fund V, L.p. .

Theseus Pharmaceuticals Inc (THRX) Insider Trades Summary

Over the past 18 months, James B. Tananbaum made no insider transaction in Theseus Pharmaceuticals Inc (THRX). Other recent insider transactions involving Theseus Pharmaceuticals Inc (THRX) include a net purchase of 700,000 shares made by Foresite Capital Fund V, L.p. , a net purchase of 479,932 shares made by Orbimed Advisors Llc , and a net purchase of 479,932 shares made by Carl L Gordon .

In summary, during the past 3 months, insiders sold 0 shares of Theseus Pharmaceuticals Inc (THRX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Theseus Pharmaceuticals Inc (THRX) were sold and 1,659,864 shares were bought by its insiders, resulting in a net purchase of 1,659,864 shares.

Theseus Pharmaceuticals Inc (THRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Theseus Pharmaceuticals Inc Insider Transactions

No Available Data

James B. Tananbaum Mailing Address

Above is the net worth, insider trading, and ownership report for James B. Tananbaum. You might contact James B. Tananbaum via mailing address: 3052 Pacific Avenue, San Francisco Ca 94115.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.